Literature DB >> 21646550

Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review.

Raveendhara R Bannuru1, Tomas Dvorak, Ndidiamaka Obadan, Winifred W Yu, Kamal Patel, Mei Chung, Stanley Ip.   

Abstract

BACKGROUND: Radiation therapy is one of many treatment options for patients with prostate cancer.
PURPOSE: To update findings on the clinical and biochemical outcomes of radiation therapies for localized prostate cancer. DATA SOURCES: MEDLINE (2007 through March 2011) and the Cochrane Central Register of Controlled Trials (2007 through March 2011). STUDY SELECTION: Published English-language comparative studies involving adults with localized prostate cancer who either had first-line radiation therapy or received no initial treatment. DATA EXTRACTION: 6 researchers extracted information on study design, potential bias, sample characteristics, interventions, and outcomes and rated the strength of overall evidence. Data for each study were extracted by 1 reviewer and confirmed by another. DATA SYNTHESIS: 75 studies (10 randomized, controlled trials [RCTs] and 65 nonrandomized studies) met the inclusion criteria. No RCTs compared radiation therapy with no treatment or no initial treatment. Among the 10 RCTs, 2 compared combinations of radiation therapies, 7 compared doses and fraction sizes of external-beam radiation therapy (EBRT), and 1 compared forms of low-dose rate radiation therapy. Heterogeneous outcomes were analyzed. Overall, moderate-strength evidence consistently showed that a higher EBRT dose was associated with increased rates of long-term biochemical control compared with lower EBRT dose. The body of evidence was rated as insufficient for all other comparisons. LIMITATIONS: Studies inconsistently defined and reported outcomes. Much of the available evidence comes from observational studies with treatment selection biases.
CONCLUSION: A lack of high-quality comparative evidence precludes conclusions about the efficacy of radiation treatments compared with no treatments for localized prostate cancer. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Year:  2011        PMID: 21646550     DOI: 10.7326/0003-4819-155-3-201108020-00347

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  The best method for dose escalation: Prostate brachytherapy.

Authors:  Gerard Morton
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

2.  Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

3.  The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Authors:  Ruth Etzioni; Roman Gulati; Alex Tsodikov; Elisabeth M Wever; David F Penson; Eveline A M Heijnsdijk; Jeffrey Katcher; Gerrit Draisma; Eric J Feuer; Harry J de Koning; Angela B Mariotto
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 4.  Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013-11       Impact factor: 1.862

5.  [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].

Authors:  T Reinhold; C Dornquast; C Börgermann; L Weißbach
Journal:  Urologe A       Date:  2016-12       Impact factor: 0.639

6.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 7.  CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Authors:  Lina Yin; Qingzhong Hu
Journal:  Nat Rev Urol       Date:  2013-11-26       Impact factor: 14.432

8.  Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up.

Authors:  Tomás Merino; Ignacio F San Francisco; Pablo A Rojas; Piero Bettoli; Alvaro Zúñiga; Pelayo Besa
Journal:  BMC Cancer       Date:  2013-11-08       Impact factor: 4.430

Review 9.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

Review 10.  Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis.

Authors:  Tengbin Xiong; Rebecca M Turner; Yinghui Wei; David E Neal; Georgios Lyratzopoulos; Julian P T Higgins
Journal:  BMJ Open       Date:  2014-05-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.